US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Heart Failure · Atrial Fibrillation · RYTM
Rhythm Pharmaceuticals Netherlands
Rhythm Pharmaceuticals Netherlands B.V.
Rhythm Pharmaceuticals Netherlands drug portfolio — 38 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
BRIGHTLANDS CHEMELOT CAMPUS, VAN ITERSON BUILDING, BURGEMEESTER LEMMENSSTRAAT 352, Geleen, nl HQ
2014 Founded
10 Employees
Public company Type
RYTM · NYSE Ticker
Company details
- Status
- Public
- HQ
- BRIGHTLANDS CHEMELOT CAMPUS, VAN ITERSON BUILDING, BURGEMEESTER LEMMENSSTRAAT 352, Geleen, nl
- Founded
- 2014
- Employees
- 10
- Programs
- 73
- Drugs
- 38
- Patents
- 12
Rhythm Pharmaceuticals Netherlands pipeline
Portfolio lens on 38 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Rhythm Pharmaceuticals Netherlands drug portfolio — 38 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
emtricitabine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records. Mechanism: Sodium channel protein type V alpha subunit blocker.
- Mechanism
- Sodium channel protein type V alpha subunit blocker
-
furosemide
Cardiovascular system (C03)US regulatory status: approved. Molecular target: Solute carrier family 12 member 1.
- Target
- Solute carrier family 12 member 1
- Mechanism
- Sodium-(potassium)-chloride cotransporter 2 inhibitor
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
insulin human
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
US regulatory status: approved.
-
setmelanotide
Alimentary tract and metabolism (A08)Alimentary tract and metabolism (A08) compound in Rhythm Pharmaceuticals Netherlands's portfolio. Molecular target: Melanocortin receptor 4.
- Target
- Melanocortin receptor 4
- Mechanism
- Melanocortin receptor 4 agonist
-
US regulatory status: approved. Molecular target: Melanocortin receptor 4.
- Target
- Melanocortin receptor 4
- Mechanism
- Melanocortin receptor 4 agonist
-
US regulatory status: approved.
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records. Mechanism: HERG blocker.
- Mechanism
- HERG blocker
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Phosphodiesterase 4 inhibitor
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Rhythm Pharmaceuticals Netherlands in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist